The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy

Peer Review reports

Original Submission
28 Mar 2011	Submitted	Original manuscript
17 May 2011	Reviewed	Reviewer Report - Kazuyuki Kawakami
25 May 2011	Reviewed	Reviewer Report - Megan Hitchins
30 May 2011	Reviewed	Reviewer Report - Wei-Peng Yong
28 Jun 2011	Author responded	Author comments - Byung-Hoon Min
Resubmission - Version 2
28 Jun 2011	Submitted	Manuscript version 2
13 Jul 2011	Reviewed	Reviewer Report - Megan Hitchins
16 Jul 2011	Reviewed	Reviewer Report - Kazuyuki Kawakami
26 Jul 2011	Author responded	Author comments - Byung-Hoon Min
Resubmission - Version 3
26 Jul 2011	Submitted	Manuscript version 3
Publishing
10 Aug 2011	Editorially accepted
10 Aug 2011	Article published	10.1186/1471-2407-11-344

Back to article page